Atherogenic dyslipidemia promotes autoimmune follicular helper T cell responses via IL-27

被引:0
作者
Heeju Ryu
Hoyong Lim
Garam Choi
Young-Jun Park
Minkyoung Cho
Hyeongjin Na
Chul Won Ahn
Young Chul Kim
Wan-Uk Kim
Sang-Hak Lee
Yeonseok Chung
机构
[1] Seoul National University,Laboratory of Immune Regulation, Institute of Pharmaceutical Sciences
[2] Seoul National University,BK21 Plus program, College of Pharmacy
[3] Seoul National University,Laboratory of Toxicology, College of Pharmacy
[4] The Catholic University of Korea,Center for Integrative Rheumatoid Transcriptomics and Dynamics
[5] Yonsei University,Division of Cardiology, Department of Internal Medicine, Severance Hospital, College of Medicine
来源
Nature Immunology | 2018年 / 19卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The incidence of atherosclerosis is higher among patients with systemic lupus erythematosus (SLE); however, the mechanism by which an atherogenic environment affects autoimmunity remains unclear. We found that reconstitution of atherosclerosis-prone Apoe–/– and Ldlr–/– mice with bone marrow from lupus-prone BXD2 mice resulted in increased autoantibody production and glomerulonephritis. This enhanced disease was associated with an increase in CXCR3+ follicular helper T cells (TFH cells). TFH cells isolated from Apoe–/– mice had higher expression of genes associated with inflammatory responses and SLE and were more potent in inducing production of the immunoglobulin IgG2c. Mechanistically, the atherogenic environment induced the cytokine IL-27 from dendritic cells in a Toll-like receptor 4 (TLR4)-dependent manner, which in turn triggered the differentiation of CXCR3+ TFH cells while inhibiting the differentiation of follicular regulatory T cells. Blockade of IL-27 signals diminished the increased TFH cell responses in atherogenic mice. Thus, atherogenic dyslipidemia augments autoimmune TFH cell responses and subsequent IgG2c production in a TLR4- and IL-27-dependent manner.
引用
收藏
页码:583 / 593
页数:10
相关论文
共 103 条
[1]  
Weber C(2011)Atherosclerosis: current pathogenesis and therapeutic options Nat. Med. 17 1410-1422
[2]  
Noels H(2006)The immune response in atherosclerosis: a double-edged sword Nat. Rev. Immunol. 6 508-519
[3]  
Hansson GK(2001)In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice Circulation 104 197-1601
[4]  
Libby P(2012)Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice Arterioscler. Thromb. Vasc. Biol. 32 273-37
[5]  
Laurat E(2005)Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s Ann. Rheum. Dis. 64 1595-2406
[6]  
Danzaki K(2008)Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002 Dermatology 217 27-18
[7]  
Goodson N(2003)Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus N. Engl. J. Med. 349 2399-398
[8]  
Marks J(2015)Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study Atherosclerosis 243 11-309
[9]  
Lunt M(2011)Clinical improvement in psoriasis with treatment of associated hyperlipidemia Am. J. Med. Sci. 341 394-227
[10]  
Symmons D(2012)New insights of T cells in the pathogenesis of psoriasis Cell. Mol. Immunol. 9 302-999